Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

Inclusion Criteria: Females must be non-pregnant and non-lactating and either surgically sterile (via hysterectomy or bilateral tubal ligation), at least one year post-menopausal, or using acceptable methods of contraception for the duration of the study. Male subjects must be surgically sterile or using an acceptable method of contraception for the duration of the study. Disease: biopsy-proven unresectable or recurrent/refractory squamoussell_eareinoma_of_the:head-and-neck-(usualLy -Stage-Di-or-IV) - Tumor accessible to direct injection Karnofsky performance of at least 70% Life expectancy of at least three months Able to give written informed consent Exclusion Criteria: Infection (concurrent or within previous 2 weeks) Active or clinically-relevant viral illnesses. Use of corticosteroids, high-dose non-steroidal antiinflammatory, or immunosuppressive drugs Chemotherapy, radiotherapy or immunotherapy within 28 days of study entry or during the course of study Respiratory disease sufficient to influence oxygenation of arterial blood Active liver disease with transaminases >3 times the upper limit of normal Previous history of liver disease NYHA Class EU or greater heart failure Serum creatinine of greater than 1.5 times the upper limit of normal Polymorphonuclear neutrophilic leukocyte count <3,000/mm3 Platelet count <50,000/mm 3 Tumor involving major blood vessels or obstructing the airway Previous treatment with viral-based gene therapy, recombinant DNA products, or bacterial plasmids Use of an investigational drug within 30 days of screening Other malignancies requiring treatment during the study Scheduled surgical resection History of autoimmune disease, including rheumatic disease, Crohn's disease, etc. , Known allergy to polyvinylpyrrofidone (PVP) or related products History of psychiatric disabilities or seizures.